Clonazepam
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Clonazepam: From Epilepsy and Anxiety Disorders to Restless Legs Syndrome
One-Sentence Summary
Clonazepam is a benzodiazepine, originally used for seizure disorders (such as absence epilepsy and Lennox-Gastaut syndrome) and anxiety disorder. The TxGNN model predicts it may be effective for restless legs syndrome (RLS), with 0 registered clinical trials but 20 publications (including a 2025 clinical practice guideline and a Cochrane systematic review) currently touching on this use.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Seizure disorders (e.g., absence epilepsy, Lennox-Gastaut syndrome, early myoclonic encephalopathy) and anxiety disorder (from the knowledge-graph indication list; the Singapore registration records do not state an approved indication) |
| Predicted New Indication | Restless legs syndrome |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L3 (systematic review and guideline, plus small older controlled studies; no registered trials) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Clonazepam is a positive allosteric modulator of the GABA-A receptor. It enhances inhibitory signalling in the brain. This is the basis for its anticonvulsant and anxiolytic effects.
RLS is a sensorimotor disorder. It causes an urge to move the legs, worse at rest and in the evening, and it often fragments sleep. Enhanced GABAergic inhibition may plausibly reduce sensory-motor arousal and sleep disruption in RLS and in periodic limb movements.
In practice, benzodiazepines, and clonazepam in particular, have long been used for RLS symptoms. One survey cited in the literature found that about 25% of 16,694 people treated for RLS received benzodiazepines. However, current guidance generally favours other drug classes (such as alpha-2-delta ligands) and iron therapy. Clonazepam is at best a second-line or conditional option.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39324694 | 2025 | Guideline | J Clin Sleep Med | American Academy of Sleep Medicine guideline with treatment recommendations for RLS and periodic limb movement disorder in adults and children |
| 28319266 | 2017 | Systematic Review | Cochrane Database Syst Rev | Cochrane review of benzodiazepines for RLS; notes clonazepam is commonly used for RLS symptoms |
| 36692194 | 2023 | Systematic review / meta-analysis | J Clin Sleep Med | Reviews which drug classes suppress periodic limb movements in sleep in RLS |
| 38708125 | 2024 | Review | Tremor Other Hyperkinet Mov | Historical overview of benzodiazepines, including clonazepam, in RLS and periodic limb movements in sleep; found 17 articles on clonazepam use |
| 11313161 | 2001 | Placebo-controlled sleep lab study | Eur Neuropsychopharmacol | Measured acute effects of 1 mg clonazepam on objective and subjective sleep in RLS and periodic limb movement disorder |
| 6380197 | 1984 | Randomized crossover trial (n=6) | Acta Neurol Scand | Clonazepam significantly improved subjective sleep quality and leg dysaesthesia vs placebo; long-term efficacy needs confirmation |
| 20156514 | 2010 | Clinical study | Prog Neuropsychopharmacol Biol Psychiatry | Proposed dose equivalence between clonazepam and pramipexole after switching patients; clonazepam is widely used for RLS in some Asian countries |
| 18925578 | 2008 | Evidence-based review | Mov Disord | Movement Disorder Society task force review of the efficacy of RLS treatments |
| 24363103 | 2014 | Review | Neurotherapeutics | Overview of changes in RLS treatment and the medication classes with demonstrated benefit |
| 26874840 | 2016 | Review | Curr Treat Options Neurol | Treatment options for intractable RLS |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17075P | Clonazepam Mevon Tablets 0.5 mg | Tablet | Not stated in the registration record |
| SIN06410P | Clonotril 0.5 Tablet 0.5 mg | Tablet | Not stated in the registration record |
Both registrations are valid, single-ingredient oral tablets.
Safety Considerations
- Contraindications (from knowledge-graph drug-disease links, not package-insert text): liver failure and liver disease, kidney disease, porphyria, respiratory failure, sleep apnoea syndromes, congenital central hypoventilation syndrome, angle-closure and open-angle glaucoma, and substance-related disorder or substance abuse/dependence. The knowledge graph also lists anxiety disorder, neurotic disorder and dysthymic disorder, which conflicts with the anxiety indication above. This needs checking against the package insert.
- Drug Interactions: 100 interactions were identified.
- Major: morphine and liposomal morphine, because of additive central nervous system and respiratory depression.
- Moderate: bupropion, aprepitant, omeprazole, cimetidine, clarithromycin, dronabinol, metoclopramide, nabilone, opium, sibutramine and teduglutide.
- Minor: several antacids, such as magnesium oxide, aluminium hydroxide and calcium carbonate.
- Class-related concerns raised in the literature: dependence, tolerance, rebound symptoms and withdrawal with benzodiazepines.
Package-insert warnings were not available for this report. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There are no registered clinical trials for RLS. The supporting evidence is a guideline, a systematic review and small older studies, and current guidance favours other first-line options. The graph-based prediction score is high, but clinical support is limited to a second-line or conditional role. Dependence risk and the respiratory-related contraindications also weigh against prioritising this use.
To proceed, the following is needed:
- Review of the full text of the 2025 AASM guideline and the Cochrane review to confirm the exact recommendation strength for clonazepam
- Controlled trial data, or a head-to-head comparison with first-line agents (alpha-2-delta ligands, dopamine agonists)
- Package-insert warnings and contraindications from the Health Sciences Authority (HSA)
- A long-term safety plan covering dependence, tolerance, sedation and falls
- A relevance check of the other predicted indications, because status epilepticus has stronger evidence (three Phase 3 trials, though this largely overlaps the existing seizure indications) and trigeminal neuralgia is also supported as a second-line option
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.